# Pediatric Malignancies Program

> **NIH NIH P30** · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · 2020 · $79,592

## Abstract

Pediatric Malignancies Program: Summary 
The Pediatric Malignancies (PE) Program focuses on malignancies unique to children (neuroblastoma, 
retinoblastoma, diffuse midline gliomas, and medulloblastoma), as well as cancers more common in children 
than adults: acute lymphoblastic leukemia (ALL), bone sarcomas, and low-grade gliomas (LGG). Pediatric solid 
tumors, often embryonal in origin, provide opportunities to understand the links between normal development 
and aberrant signaling in childhood malignancies; to discover therapeutic targets; and to integrate these 
discoveries into innovative clinical trials. Inherited cancer predispositions, common in pediatric cancers, offer 
opportunities to uncover genes and proteins that regulate normal growth and are deregulated in cancer. These 
molecular studies also inform interactions between tumors and the tumor microenvironment in cancer 
development, understanding the late effects of treatment, and improving the outcome for survivors. 
The overall goals of the PE Program are (1) to understand the biology of pediatric malignancies and uncover 
links between normal development and cancer to identify therapeutic targets; and (2) to translate laboratory 
discoveries into clinical trials, and epidemiological and survivorship studies to improve clinical outcomes for 
children with cancer. These goals are addressed by undertaking research in four disease-specific themes: 
 Theme 1: Acute leukemia 
 Theme 2: Brain tumors 
 Theme 3: Neuroblastoma 
 Theme 4: Sarcoma and other pediatric solid tumors 
PE Program: Key Metrics 
Membership (12 departments, 2 schools) 30 
Full 23 
Associate 7 
Cancer-relevant Funding (direct costs as of 
$14,090,085 
05/31/2017) 
NCI $4,160,966 30% 
Peer-reviewed $5,888,503 42% 
Non-peer-reviewed $4,040,617 29% 
Cancer-relevant Publications (1/2012-7/2017) 506 
Inter-programmatic 201 40% 
Intra-Programmatic 139 27% 
High-Impact 184 36% 
Accruals to Clinical Trials (2016) 188 85 
Therapeutic 88 67 
Other Interventional 2 5 
Non-interventional 98 13

## Key facts

- **NIH application ID:** 9965776
- **Project number:** 5P30CA082103-21
- **Recipient organization:** UNIVERSITY OF CALIFORNIA, SAN FRANCISCO
- **Principal Investigator:** WILLIAM A WEISS
- **Activity code:** P30 (R01, R21, SBIR, etc.)
- **Funding institute:** NIH
- **Fiscal year:** 2020
- **Award amount:** $79,592
- **Award type:** 5
- **Project period:** — → —

## Primary source

NIH RePORTER: https://reporter.nih.gov/project-details/9965776

## Citation

> US National Institutes of Health, RePORTER application 9965776, Pediatric Malignancies Program (5P30CA082103-21). Retrieved via AI Analytics 2026-05-23 from https://api.ai-analytics.org/grant/nih/9965776. Licensed CC0.

---

*[NIH grants dataset](/datasets/nih-grants) · CC0 1.0*